Addressing a Growing Demand for Plasma-Derived Therapies

Joerg Schuettrumpf, chief scientific innovation officer at Grifols, discusses the changing landscape for primary immunodeficiency disorders, the challenges of ensuring a reliable supply of plasma-derived therapies, and how treatment options may evolve.